乐沙定联合氟脲嘧啶、甲酰四氢叶酸治疗进展期大肠癌21例分析

A Clinical Study of Eloxatin Combined with 5－FU／FA in Treatment of Patients with Advanced Colorectal Cancer

目的：评价乐沙定（奥沙利铂）联合氟脲嘧啶、甲酰四氢叶酸治疗进展期大肠癌的近期疗效和不良反应。方法：进行开放性的临床研究，乐沙定130mg／m2静脉滴注2小时d1，甲酰四氢叶酸（FA）200mg／m2静脉滴注2小时d1～5，5－氟脲嘧啶（5－FU）300mg／m2静脉滴注4小时d1～5，每3周重复1次。治疗3周期后评价疗效，有效病例4周后确认疗效。按WHO标准进行疗效评价。结果：共治疗21例，其中20例可评价疗效：PR 6例，SD 9例，PD 5例，总有效率30．0％。不良反应主要为感觉神经毒性，胃肠道反应及贫血。结论：本方案治疗进展期大肠癌近期疗效与国内外报告结果相近，不良反应轻，多数患者耐受良好，是治疗大肠癌理想的联合化疗方案。

Objective: To evaluate the efficacy and adverse effects of eloxatin (oxaliplatin, L－OHP) combined with 5－fluorouracil (5－FU)／folinic acid (FA) in treatment of patients with advanced colorectal cancer (ACRC)． Methods: An open clinical study of this regimen was conducted． L－OHP 130mg／m2, iv infusion for 2h－D1 combined with FA 200mg／m2 iv infusion for 2h followed by 5－FU 300mg／m2 iv infusion for 4hD1 to D5, repeated every 3 weeks． Tumor assessment was done after 3 cycles and the responders were confirmed 4 weeks later． Results: Twenty－one ACRC patients entered this study, 20 cases were evaluable for efficacy: PR 6 cases, SD 9 cases, PD 5 cases． The overall response rate was 30．0％． The main adverse effects were neurosensory toxicity, while bone marrow suppression was mild． Conclusion: This study suggested that the short－term curative effect of this regimen is similar to the universal effects and it is a new option for the treatment of advanced colorectal cancer．